PBA
MIST icon

Paradigm Biocapital Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Paradigm Biocapital Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-634,211
Closed -$5.83M – 27
2022
Q3 		$5.83M Buy
+634,211
New +$4.81M 0.78% 28

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Paradigm Biocapital Advisors's MIST Position: Q4 2022 in Review

Paradigm Biocapital Advisors sold out of Milestone Pharmaceuticals (MIST) in Q4 2022, closing a stake of 634,211 shares — an estimated $5.83M sold.

Paradigm Biocapital Advisors first reported a position in MIST in Q3 2022 and held it in 1 quarter. The position peaked at $5.83M in Q3 2022. 56 funds tracked by Wall St. Rank hold MIST as of Q4 2022.

  • Paradigm Biocapital Advisors reported no remaining Milestone Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 634,211 Milestone Pharmaceuticals shares in Q4 2022, an estimated $5.83M.
  • Paradigm Biocapital Advisors first reported a position in Milestone Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Milestone Pharmaceuticals position peaked at $5.83M in Q3 2022.
  • 56 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.